{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:47:25Z","timestamp":1791082045068,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.bbrc.2024.150170","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:36:39Z","timestamp":1716492999000},"page":"150170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob\/ob mice"],"prefix":"10.1016","volume":"722","author":[{"given":"Bin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijiao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0305-3127","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2826-5804","authenticated-orcid":false,"given":"Yunfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2024.150170_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2024.150170_bib2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2024.150170_bib3","doi-asserted-by":"crossref","first-page":"7571","DOI":"10.3390\/ijms22147571","article-title":"Current options and future directions for NAFLD and NASH treatment","volume":"22","author":"Zhang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2024.150170_bib4","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: definition and subtypes","volume":"29","author":"Han","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.bbrc.2024.150170_bib5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2024.150170_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/d41573-024-00051-1","article-title":"NASH field celebrates 'hurrah moment' with a first FDA drug approval for the liver disease","volume":"23","author":"Kingwell","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2024.150170_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nm.4461","article-title":"The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis","volume":"24","author":"Ji","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2024.150170_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2024.150170_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tips.2019.05.002","article-title":"Genetic insights for drug development in NAFLD","volume":"40","author":"Eslam","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2024.150170_bib10","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bbrc.2024.150170_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/obr.12385","article-title":"Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders","volume":"17","author":"Wu","year":"2016","journal-title":"Obes. Rev."},{"key":"10.1016\/j.bbrc.2024.150170_bib12","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.cgh.2014.01.040","article-title":"Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis","volume":"12","author":"Ratziu","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2024.150170_bib13","article-title":"LncRNA GAS5 knockdown mitigates hepatic lipid accumulation via regulating MiR-26a-5p\/PDE4B to activate cAMP\/CREB pathway","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbrc.2024.150170_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/fcp.12530","article-title":"Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high\u2010fat diet\u2010induced nonalcoholic fatty liver in rats","volume":"34","author":"El Deen","year":"2020","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2024.150170_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106906","article-title":"Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and acos","volume":"88","author":"Bodkhe","year":"2020","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.bbrc.2024.150170_bib16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/labinvest.2017.59","article-title":"Roflumilast reverses polymicrobial sepsis-induced liver damage by inhibiting inflammation in mice","volume":"97","author":"Feng","year":"2017","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bbrc.2024.150170_bib17","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/cts.13235","article-title":"Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet\u2010induced obese and biopsy\u2010confirmed mouse model of NASH","volume":"15","author":"M\u00f8llerh\u00f8j","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bbrc.2024.150170_bib18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12876-020-01356-2","article-title":"Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis","volume":"20","author":"Hansen","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.bbrc.2024.150170_bib19","first-page":"1707","article-title":"Mouse models of nonalcoholic steatohepatitis in preclinical drug development","volume":"22","author":"Hansen","year":"2017","journal-title":"Drug Discov."},{"key":"10.1016\/j.bbrc.2024.150170_bib20","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.3748\/wjg.v25.i33.4904","article-title":"Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: impact of dietary fat source","volume":"25","author":"Boland","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2024.150170_bib21","article-title":"A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis","volume":"18","author":"Li","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2024.150170_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s12272-022-01410-5","article-title":"Mouse models of nonalcoholic steatohepatitis and their application to new drug development","volume":"45","author":"Phung","year":"2022","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.bbrc.2024.150170_bib23","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jhep.2023.01.024","article-title":"An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease","volume":"78","author":"Lee","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2024.150170_bib24","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.advnut.2023.08.005","article-title":"Dietary regulation of hepatic triacylglycerol content\u2014the role of eucaloric carbohydrate restriction with fat or protein replacement","volume":"14","author":"Lundsgaard","year":"2023","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.bbrc.2024.150170_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fendo.2020.00070","article-title":"Effect of weight loss medications on hepatic steatosis and steatohepatitis: a systematic review","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbrc.2024.150170_bib26","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.3390\/nu15183987","article-title":"Dietary patterns, foods, and nutrients to ameliorate non-alcoholic fatty liver disease: a scoping review","volume":"15","author":"Montemayor","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.bbrc.2024.150170_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbrc.2024.150170_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121806","article-title":"Roflumilast ameliorates ovariectomy-induced depressive-like behavior in rats via activation of AMPK\/mTOR\/ULK1-dependent autophagy pathway","volume":"327","author":"Zaki","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2024.150170_bib29","doi-asserted-by":"crossref","DOI":"10.1289\/EHP10092","article-title":"Exposure to per- and polyfluoroalkyl substances and markers of liver injury: a systematic review and meta-analysis","volume":"130","author":"Costello","year":"2022","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.bbrc.2024.150170_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113869","article-title":"Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis","volume":"176","author":"Kumar","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2024.150170_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.lfs.2019.03.014","article-title":"Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: modulation of cAMP\/CREB\/TLR4 inflammatory and fibrogenic pathways","volume":"222","author":"Essam","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2024.150170_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.597583","article-title":"Pathophysiology of NAFLD and NASH in experimental models: the role of food intake regulating peptides","volume":"11","author":"Korinkova","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbrc.2024.150170_bib33","doi-asserted-by":"crossref","first-page":"9324","DOI":"10.3390\/ijms24119324","article-title":"Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2024.150170_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1046130","article-title":"Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model","volume":"13","author":"Niu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbrc.2024.150170_bib35","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00125-012-2632-z","article-title":"The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db\/db mice","volume":"55","author":"Vollert","year":"2012","journal-title":"Diabetologia"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2400706X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2400706X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T17:01:41Z","timestamp":1727370101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X2400706X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":35,"alternative-id":["S0006291X2400706X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.150170","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob\/ob mice","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.150170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150170"}}